Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 2/20 | 0.85 |
| ▸ | MEN1 | O00255 | 1/20 | 0.85 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.85 |
| ▸ | LMNA | P02545 | 1/20 | 0.85 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.85 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.85 |
| ▸ | VCP | P55072 | 1/20 | 0.85 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.85 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.85 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.85 |
| ▸ | HPRT1 | P00492 | 9/20 | 0.66 |
| ▸ | PNP | P00491 | 6/20 | 0.65 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.64 |
| ▸ | POLG | P54098 | 2/20 | 0.64 |
| ▸ | USP2 | O75604 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | EDNRA | P25101 | 1/20 | 0.60 |
| ▸ | HTR2A | P28223 | 1/20 | 0.60 |
| ▸ | RECQL | P46063 | 1/20 | 0.60 |
| ▸ | HBB | P68871 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ganciclovir SCHEMBL6047042 | 0.95 | BLM (0.91) | BLMMEN1ALDH1A1LMNACYP3A4 | |
| Ganciclovir SCHEMBL1061493 | 0.95 | BLM (0.91) | BLMMEN1ALDH1A1LMNACYP3A4 | |
| Ganciclovir SCHEMBL634653 | 0.95 | BLM (0.91) | BLMMEN1ALDH1A1LMNACYP3A4 | |
| Ganciclovir SCHEMBL2160505 | 0.92 | BLM (1.00) | BLMMEN1ALDH1A1LMNACYP3A4 | |
| Ganciclovir SCHEMBL3033 | 0.92 | BLM (1.00) | BLMMEN1ALDH1A1LMNACYP3A4 | |
| Ganciclovir SCHEMBL1242615 | 0.91 | BLM (0.98) | BLMMEN1ALDH1A1LMNACYP3A4 | |
| Ganciclovir SCHEMBL10899902 | 0.91 | BLM (0.98) | BLMMEN1ALDH1A1LMNACYP3A4 | |
| Ganciclovir SCHEMBL10481436 | 0.91 | BLM (0.98) | BLMMEN1ALDH1A1LMNACYP3A4 | |
| Ganciclovir SCHEMBL10481442 | 0.91 | BLM (0.98) | BLMMEN1ALDH1A1LMNACYP3A4 | |
| Ganciclovir SCHEMBL11093368 | 0.91 | BLM (0.98) | BLMMEN1ALDH1A1LMNACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5223263-A | Viricide complex; aids therapy | VICAL, INC. (US) | 1993-06-29 | — | — | US | claimed |
| EP-0138656-B1 | CYCLIC PYROPHOSPHATES OF PURINE AND PYRIMIDINE ACYCLONUCLEOSIDES, THEIR PREPARATION AND THEIR APPLICATION IN ANTI-VIRAL COMPOSITIONS | MERCK & CO. INC. (US) | 1989-09-27 | — | — | EP | claimed |
| CN-119907678-A | Medicaments (variants) for combining gene-directed enzyme prodrug therapy with immunotherapy for the treatment of solid malignancies | 吉那亚希鲁尔吉亚有限责任公司 | 2025-04-29 | — | — | CN | disclosed |
| CN-118634346-A | Altering eye color by gene transduction | 詹姆斯·W·希尔 | 2024-09-13 | — | — | CN | disclosed |
| WO-2024049326-A1 | MEDICINAL PREPARATION FOR COMBINED GENE-DIRECTED ENZYME PRODRUG THERAPY AND IMMUNOTHERAPY OF SOLID MALIGNANT TUMOURS (EMBODIMENTS) | Общество с ограниченной ответственностью "Генная Хирургия" | 2024-03-07 | — | — | WO | disclosed |
| US-20230277428-A1 | Changing Eye Color by Gene Transduction | HILL JAMES W (US) | 2023-09-07 | — | — | US | disclosed |
| US-11622927-B2 | Changing eye color by gene transduction | Hill, James W. (US) | 2023-04-11 | — | — | US | disclosed |
| EP-4090384-A1 | CHANGING EYE COLOR BY GENE TRANSDUCTION | Hill, James, W. (US) | 2022-11-23 | — | — | EP | disclosed |
| CN-115175707-A | Changing eye color by gene transduction | 詹姆斯·W·希尔 | 2022-10-11 | — | — | CN | disclosed |
| US-20220313585-A1 | Changing Eye Color by Gene Transduction | JAMES W HILL (US) | 2022-10-06 | — | — | US | disclosed |
| EP-4056031-A1 | METHODS AND COMPOSITIONS RELATING TO IMPROVED HUMAN RED BLOOD CELL SURVIVAL IN GENETICALLY MODIFIED IMMUNODEFICIENT NON-HUMAN ANIMALS | The Jackson Laboratory (US) | 2022-09-14 | — | — | EP | disclosed |
| WO-2001072280-A2 | MICROSPHERES FOR GENE THERAPY | BIOSPHERE MEDICAL INC. (US) | 2001-10-04 | — | — | WO | disclosed |
| WO-2001072281-A2 | MICROSPHERES FOR ACTIVE EMBOLIZATION | BIOSPHERE MEDICAL INC. (US) | 2001-10-04 | — | — | WO | disclosed |
| EP-0523189-B1 | CATIONIC LIPIDS FOR INTRACELLULAR DELIVERY OF BIOLOGICALLY ACTIVE MOLECULES | VICAL INC (US) | 1999-06-16 | — | — | EP | disclosed |
| EP-0910654-A1 | ENZYME COMBINATIONS FOR DESTROYING PROLIFERATIVE CELLS | Aventis Pharma S.A. (FR) | 1999-04-28 | — | — | EP | disclosed |
| WO-1997035024-A1 | ENZYME COMBINATIONS FOR DESTROYING PROLIFERATIVE CELLS | RHONE-POULENC RORER S.A. (FR) | 1997-09-25 | — | — | WO | disclosed |
| US-5459127-A | Drug delivery, extracellular treatment | VICAL, INC. (US) | 1995-10-17 | — | — | US | disclosed |
| US-5264618-A | For transport of biological active agents into cells for viral agents or polynucleotides or immunogenic peptides | VICAL, INC. (US) | 1993-11-23 | — | — | US | disclosed |
| EP-0523189-A1 | CATIONIC LIPIDS FOR INTRACELLULAR DELIVERY OF BIOLOGICALLY ACTIVE MOLECULES | VICAL, INC. (US) | 1993-01-20 | — | — | EP | disclosed |
| WO-1991016024-A1 | CATIONIC LIPIDS FOR INTRACELLULAR DELIVERY OF BIOLOGICALLY ACTIVE MOLECULES | VICAL, INC. (US) | 1991-10-31 | — | — | WO | disclosed |